Compare TDW & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | ERAS |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | United States |
| Employees | 7300 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2021 |
| Metric | TDW | ERAS |
|---|---|---|
| Price | $76.19 | $19.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $81.33 | $14.25 |
| AVG Volume (30 Days) | 817.3K | ★ 5.6M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | $12.34 | N/A |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.65 | $1.33 |
| 52 Week High | $93.13 | $24.28 |
| Indicator | TDW | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 60.29 |
| Support Level | $71.32 | $17.63 |
| Resistance Level | $77.25 | $24.28 |
| Average True Range (ATR) | 2.32 | 1.29 |
| MACD | 1.11 | -0.04 |
| Stochastic Oscillator | 94.15 | 45.41 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments, including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.